Literature DB >> 1615119

Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.

M Sarter1, J Hagan, P Dudchenko.   

Abstract

Preclinical efforts to detect and characterize potential cognition enhancers appear to have been dominated by a strategy of demonstrating a wide variety of apparently beneficial behavioral effects with little attention given to the specific psychological mechanisms underlying behavioral enhancement. In particular, the question of whether or not behavioral facilitation is based on relevant mnemonic mechanisms and is independent of the stimulus properties and/or the motivational and attentional components of a task is not often considered. As a result, an overwhelming number of compounds have failed to produce the clinical effects predicted for them on the basis of preclinical research. The available data suggest that a more successful approach requires deductive research strategies rather than the indiscriminate accumulation of apparently beneficial effects in a variety of behavioral tasks and animal models. The first step towards such an approach is a systematic and rigorous evaluation of the different aspects of validity for the models most frequently used in preclinical research. It is concluded that a combination of good construct validity and good face validity represents a necessary condition for screening tests with predictive validity, and that the most popular paradigms fail to fulfil these criteria. Future screening programs for cognition enhancers will probably be characterized by a depreciation of "fast and dirty tests" in favor of approaches focussing on the validity of the effects of potential cognition enhancers.

Mesh:

Substances:

Year:  1992        PMID: 1615119     DOI: 10.1007/bf02245132

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  144 in total

1.  Effects of the novel compound, Hoe 065, upon impaired learning and memory in rodents.

Authors:  F J Hock; H J Gerhards; G Wiemer; J Stechl; W Rüger; H Urbach
Journal:  Eur J Pharmacol       Date:  1989-11-14       Impact factor: 4.432

Review 2.  Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.

Authors:  C D Nicholson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Pharmacological approaches in the treatment of senile dementia.

Authors:  R Markstein
Journal:  Eur Neurol       Date:  1989       Impact factor: 1.710

4.  Intracerebroventricular bethanechol chloride infusion in Alzheimer's disease. Results of a collaborative double-blind study.

Authors:  R E Harbaugh; T M Reeder; H J Senter; D S Knopman; D S Baskin; F Pirozzolo; H C Chui; A G Shetter; R A Bakay; R Leblanc
Journal:  J Neurosurg       Date:  1989-10       Impact factor: 5.115

Review 5.  The cholinergic hypothesis--ten years on.

Authors:  E K Perry
Journal:  Br Med Bull       Date:  1986-01       Impact factor: 4.291

6.  Piracetam combined with lecithin in the treatment of Alzheimer's disease.

Authors:  J H Growdon; S Corkin; F J Huff; T J Rosen
Journal:  Neurobiol Aging       Date:  1986 Jul-Aug       Impact factor: 4.673

Review 7.  Attenuation of experimentally-induced amnesia.

Authors:  J L Martinez; R A Jensen; J L McGaugh
Journal:  Prog Neurobiol       Date:  1981       Impact factor: 11.685

8.  Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice.

Authors:  J E Sweeney; E S Bachman; J T Coyle
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Tetrahydroaminoacridine improves the spatial acquisition deficit produced by nucleus basalis lesions in rats.

Authors:  P F Kwo-On-Yuen; R Mandel; A D Chen; L J Thal
Journal:  Exp Neurol       Date:  1990-06       Impact factor: 5.330

10.  Enhancement of learning and memory in mice by a benzodiazepine antagonist.

Authors:  H Lal; B Kumar; M J Forster
Journal:  FASEB J       Date:  1988-08       Impact factor: 5.191

View more
  23 in total

1.  Smart drugs: Implications of student use.

Authors:  R J Canterbury; E Lloyd
Journal:  J Prim Prev       Date:  1994-03

Review 2.  Cognition enhancers in age-related cognitive decline.

Authors:  W J Riedel; J Jolles
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

3.  Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms.

Authors:  S Caccia; S Confalonieri; G Guiso; P Bernasconi; A Cagnotto; M Skorupska; T Mennini
Journal:  Psychopharmacology (Berl)       Date:  1994-08       Impact factor: 4.530

4.  Effects of disrupting the cholinergic system on short-term spatial memory in rats.

Authors:  J S Andrews; J H Jansen; S Linders; A Princen
Journal:  Psychopharmacology (Berl)       Date:  1994-08       Impact factor: 4.530

5.  Attenuation of scopolamine-induced spatial memory deficits in the rat by cholinomimetic and non-cholinomimetic drugs using a novel task in the 12-arm radial maze.

Authors:  R P Dennes; J C Barnes
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Scopolamine impairs auditory delayed matching-to-sample performance in monkeys.

Authors:  Bethany Plakke; Chi-Wing Ng; Amy Poremba
Journal:  Neurosci Lett       Date:  2008-04-10       Impact factor: 3.046

7.  Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats.

Authors:  J Turchi; L A Holley; M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 8.  A pharmacological analysis of an associative learning task: 5-HT(1) to 5-HT(7) receptor subtypes function on a pavlovian/instrumental autoshaped memory.

Authors:  Alfredo Meneses
Journal:  Learn Mem       Date:  2003 Sep-Oct       Impact factor: 2.460

Review 9.  Improved behavioral response as a valid biomarker for drug screening program in transgenic rodent models of tauopathies.

Authors:  Miroslava Korenova; Zuzana Stozicka
Journal:  Cell Mol Neurobiol       Date:  2009-03-13       Impact factor: 5.046

Review 10.  The reinstatement model and relapse prevention: a clinical perspective.

Authors:  David H Epstein; Kenzie L Preston
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.